Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222813 | 0.87 | PIK3CG (0.68) | PIK3CGPIK3CAPIK3CDABL1 | |
| SCHEMBL220646 | 0.84 | ABL1 (0.53) | ABL1 | |
| SCHEMBL1708588 | 0.83 | NPC1 (0.53) | PIK3CGPIK3CAPIK3CDABL1NPC1 | |
| SCHEMBL222918 | 0.82 | PIK3CA (0.46) | PIK3CGPIK3CAPIK3CDABL1NPC1 | |
| SCHEMBL2739677 | 0.81 | MAPK1 (0.49) | PIK3CGPIK3CAABL1NPC1RAB9A | |
| SCHEMBL2739669 | 0.80 | NPC1 (0.47) | PIK3CGPIK3CAPIK3CDABL1NPC1 | |
| SCHEMBL12543310 | 0.80 | PIK3CG (0.76) | PIK3CGPIK3CAPIK3CDABL1NPC1 | |
| SCHEMBL15260270 | 0.79 | NPC1 (0.43) | PIK3CGPIK3CAPIK3CDABL1NPC1 | |
| SCHEMBL222045 | 0.79 | PIK3CA (0.50) | PIK3CGPIK3CAPIK3CDABL1NPC1 | |
| SCHEMBL220904 | 0.79 | NPC1 (0.54) | PIK3CGPIK3CAPIK3CDABL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004221-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | PIK3CG 3492/4885PIK3CA 4048/4885PIK3CD 3480/4885 |
| US-20110263590-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | PIK3CG 3467/4885PIK3CA 4048/4885PIK3CD 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.